


NVALT 19 Overzicht

Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase II study. NVALT 19.



Primary endpoint

progression-free survival.

Secondary endpoints

- Adverse events
- Objective radiological response rate in patients with measurable disease
- Overall survival
- Changes in vital capacity and FEV1

Total 124 patients
Study Coordinator Dr. J.A. Burgers, M.D., Ph.D.
s.burgers@nki.nl tel nr: 020 512 2947

Central Data Management NVALT Datacenter, Amsterdam